Pharmaceutical giants Pfizer and Novartis were first to gain regulatory approval with drugs that block a pair of enzymes important to tumor growth in breast cancer. Clinical-stage biotech G1 Therapeutics has a different approach to those same enzymes and will ask investors in the public markets to get on board.